New drug aims to stop relapses in rare brain disease
NCT ID NCT03330418
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called RC18 in 178 people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal was to see if RC18 could prevent relapses and slow disability. Participants had to have had recent relapses and test positive for a specific antibody. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study hopes to find a simple test for MS diagnosis
- Massive italian MS registry aims to unlock secrets of the disease
- Silent attacks in NMOSD: new study aims to predict disability before it strikes
- New shot aims to stop devastating NMOSD Flare-Ups
- Could a zappy headband cure insomnia in MS patients?
- Engineered immune cells take aim at multiple sclerosis and myasthenia gravis